MYCN and rhabdomyosarcoma: MYCN is overexpressed, frequently as a consequence of genomic amplification, in a large number of childhood malignancies, such as neuroblastoma, rhabdomyosarcoma and medulloblastoma, and enhanced MYCN expression correlates with increased growth potential and dismal prognosis [14-18].